Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Bortezomib in Treating Patients With Myelodysplastic Syndromes

This study has been completed.
Information provided by (Responsible Party):
University of Rochester Identifier:
First received: December 6, 2005
Last updated: September 16, 2014
Last verified: September 2014

December 6, 2005
September 16, 2014
May 2005
October 2010   (final data collection date for primary outcome measure)
  • Safety as measured by NCI toxicity criteria after every course [ Time Frame: For 21 days/course for up to 12 courses ] [ Designated as safety issue: Yes ]
  • Efficacy as measured by improvement of cytopenias based on complete blood counts after every course [ Time Frame: 21 Days/course for up to 12 courses ] [ Designated as safety issue: No ]
Not Provided
Complete list of historical versions of study NCT00262873 on Archive Site
Marrow and karyotype response and in vitro correlates (apoptosis, proliferation, etc.) assessed with marrow aspirate and biopsy sampling at baseline, day 14, and after courses 3, 6, and 12 [ Time Frame: 21 Days/course for up to 12 courses ] [ Designated as safety issue: No ]
Not Provided
Not Provided
Not Provided
Bortezomib in Treating Patients With Myelodysplastic Syndromes
A Phase II Pilot Study of VELCADE in Patients With MDS

RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

PURPOSE: This phase II trial is studying how well bortezomib works in treating patients with myelodysplastic syndromes.



  • Determine the efficacy of bortezomib, in terms of reduced cytopenia, in patients with myelodysplastic syndromes.
  • Determine the safety and toxic effects of this drug in these patients.


  • Determine changes in marrow blast percentage or karyotypic profile in patients treated with this drug.

OUTLINE: This is an open-label study.

Patients receive bortezomib IV on days 1, 4, 8, and 11. Treatment repeats every 21 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed periodically for 1 year.

PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study.

Phase 2
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Myelodysplastic Syndromes
Drug: bortezomib
Experimental: Bortezomib
Intervention: Drug: bortezomib
Liesveld JL, Rosell KE, Bechelli J, Lu C, Messina P, Mulford D, Ifthikharuddin JJ, Jordan CT, Phillips Ii GL. Proteasome inhibition in myelodysplastic syndromes and acute myelogenous leukemia cell lines. Cancer Invest. 2011 Aug;29(7):439-50. doi: 10.3109/07357907.2011.590567.

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
October 2010
October 2010   (final data collection date for primary outcome measure)


  • Diagnosis of myelodysplastic syndromes (MDS)
  • Requires treatment or transfusion support for MDS, as indicated by 1 of the following:

    • Demonstrates transfusion or epoetin alfa dependence

      • Transfusion dependence is defined as requiring ≥ 2 units of packed RBCs within an 8-week period prior to study entry
    • Hemoglobin < 11g/dL on 2 separate occasions 2 weeks apart

      • No iron, cyanocobalamin (vitamin B_12), or folic acid deficiency or other causes of anemia
  • Must have 1 of the following FAB subtypes:

    • Refractory anemia
    • Refractory anemia with ringed sideroblasts
    • Refractory anemia with excess blasts
    • Secondary MDS (if ≥ 3 years since active primary cancer)
  • No chronic myelomonocytic leukemia
  • Not refractory to platelet transfusion support (i.e., inability to maintain platelet count > 20,000/mm^3 with transfusion)
  • No current acute myelogenous leukemia (e.g., > 30% blasts)


Performance status

  • Karnofsky 50-100%

Life expectancy

  • At least 6 months


  • See Disease Characteristics


  • Bilirubin ≤ 2 mg/dL
  • AST and ALT < 2 times upper limit of normal


  • Creatinine clearance ≥ 30 mL/min


  • No significant cardiovascular condition that would preclude study participation
  • No uncontrolled hypertension


  • No significant pulmonary condition that would preclude study participation


  • No serious concurrent infection

    • Active infections must be adequately treated with antibiotics prior to study entry
  • No hypersensitivity to bortezomib, boron, or mannitol


  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception during and for up to 4 weeks after completion of study treatment
  • No peripheral neuropathy ≥ grade 2
  • No uncontrolled seizure activity, as defined by no activity within the past year on stable anticonvulsant medications
  • No other malignancy within the past 3 years except adequately treated basal cell skin cancer or carcinoma in situ of the cervix
  • No endocrine, neurologic, or other systemic disease that would preclude study entry


Biologic therapy

  • See Disease Characteristics
  • No prior allogeneic bone marrow transplantation
  • Concurrent transfusion support allowed
  • Concurrent epoetin alfa or darbepoetin alfa allowed if initiated before start of study therapy, dose is stable for ≥ 4 weeks, and dose is stable during study participation
  • No concurrent platelet growth factor support
  • No concurrent thalidomide


  • No concurrent chemotherapy
  • No concurrent hydroxyurea

Endocrine therapy

  • Concurrent corticosteroids for chronic autoimmune or inflammatory condition allowed if initiated before start of study therapy and maintained on a stable or decreasing dose


  • Recovered from all prior therapies
  • At least 4 weeks since prior MDS therapy, except epoetin alfa, darbepoetin alfa, filgrastim (G-CSF), pegfilgrastim (G-CSF), or transfusion support
  • At least 30 days since prior investigational agents
  • No prior bortezomib
  • No other concurrent investigational agents
  • No other concurrent therapy for MDS
18 Years and older
Contact information is only displayed when the study is recruiting subjects
United States
CDR0000449689, URCC-U20403, MILLENNIUM-i34103-042
Not Provided
University of Rochester
University of Rochester
Not Provided
Study Chair: Jane L. Liesveld, MD James P. Wilmot Cancer Center
University of Rochester
September 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP